Effect of COVID-19 on c-reactive protein and d-dimer

Wael Mohammed Mahdi and Amidah Ali Atiyah

 Department of Pathological Analysis, College of Applied Sciences, University of   Samarra, Samarra, Iraq

*Corresponding author: biologistami.iq30@yahoo.com

Received: July 18, 2021 / Revised: Aug 5, 2021/ Accepted: Aug 10, 2021

Abstract

Since December 2019, the International Committee on Taxonomy of Viruses (ICTV) has formally designated a novel human coronavirus found in Wuhan, China, as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a new RNA virus strain that belongs to the beta-coronavirus 2b families in the evolutionary tree. COVID-19 had a reported overall case-fatality rate (CFR) of 2.3 percent by this time, while cases in those aged 70 to 79 years had an 8.0 percent CFR and cases in those aged 80 and above had a 14.8 percent CFR. Severe pulmonary and extrapulmonary problems can result in respiratory failure and life-threatening events in certain individuals. D-dimer levels were found to be elevated in nearly half of the patients, and aberrant D-dimer levels are linked to a bad prognosis. As a result, in some stable individuals who die suddenly, acute organ failure, embolism, and infarction should be considered. Although the incidence of thrombosis in COVID-19 patients has not been identified, deep vein thrombosis (DVT) and pulmonary embolism (PE) were found to be 20.5 percent and 11.4 percent in SARS cases, respectively.

Keywords  COVID-19, C- reactive protein, D-dimer, Coronavirus, Respiratory Disease

How to cite this article:

Mahdi, W.M. and Atiyah, A.A. (2021). Effect of COVID-19 on c-reactive protein and d-dimer. Science Archives, Vol. 2 (3), 175-181. http://dx.doi.org/10.47587/SA.2021.2304

Copyright

This is an open-access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

Agapakis, D.I., Tsantilas, D., Psarris, P., Massa, E.V., Kotsaftis, P., Tziomalos, K., Hatzitolios, A.I. (2010). Coagulation and inflammation biomarkers may help predict the severity of community-acquired pneumonia. Respirology, 15(5):796–803

Amgalan, A., Othman, M. (2020). Hemostatic laboratory derangements in COVID-19 with a focus on platelet count. Platelets, 31:740–5.

Assiri, A., Al-Tawfiq, J.A., Al-Rabeeah, A.A. et al. (2013). Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis, 13(9):752–761.

Aziz, M., Fatima, R., Lee-Smith, W. Assaly, R. (2020). The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis. Crit Care, 24:255.

Bal, A., Agrawal, R., Vaideeswar, P., Arava, S., Jain, A. (2020). COVID-19: an up-to-date review—from morphology to pathogenesis. Indian J Pathol Microbiol, 63:358–66.

Bao, C., Tao, X., Cui, W., Yi, B., Pan, T., Young, K.H. et al. (2020). SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients. Exp Hematol Oncol, 9:16.

Bellmann-Weiler, R., Lanser, L., Barket, R., Rangger, L., Schapfl, A., Schaber, M. et al. (2020). Prevalence and predictive value of anemia and dysregulated iron homeostasis in patients with COVID-19 Infection. J ClinMed, 9:E2429.

Bone, R.C.,Grodzin, C.J., Balk, R.A. (1997). Sepsis: a new hypothesis for pathogenesis of the disease process. Chest, 112(1):235–243

Caliendo, A.M., Gilbert, D.N.,Ginocchio, C.C. et al. (2013). Better Tests, Better Care: Improved Diagnostics for Infectious Diseases. Clinical Infectious Diseases, 57(3):139–170.

Catanzaro, M., Fagiani, F., Racchi, M., Corsini, E., Govoni, S., Lanni, C. (2020). Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther, 5:84.

Chen, N., Zhou, M., Dong, X. et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 395(10223):507–513.

Chen, R., Sang, L., Jiang, M., Yang, Z., Jia, N., Fu, W. et al. (2020). Medical treatment expert group for COVID-19. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. J Allergy Clin Immmunol, 146:89–100.

Chong, P.Y., Chui, P., Ling, A.E. et al. (2004). Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med, 128(2):195–204.

Corman, V.M., Landt, O., Kaiser, M. et al. (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill, 25(3):2000045.

Cui, X., Zhao, Z., Zhang, T., Guo, W., Guo, W., Zheng, J. et al. (2021). A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19). J Med Virol, 93:1057–69.

D’ardes, D., Boccatonda, A., Rossi, I., Guagnano, M. T., Santilli, F., Cipollone, F. et al. (2020). COVID-19 and RAS: unraveling an unclear relationship. Int JMol Sci, 21:3003.

Davies, P., Evans, C., Kanthimathinathan, H.K., Lillie, J., Brierley, J., Waters, G. et al. (2020). Intensive care admissions of children with paediatric inflammatory multisystemsyndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health, 4:669–77.

Dhanalakshmi, K., Venkataraman, A., Balasubramanian, S., Madhusudan, M., Amperayani, S., Putilibai, S. et al. (2020). Epidemiological and clinical profile of pediatric inflammatory multisystem syndrome—temporally associated with SARS-CoV-2 (PIMS-TS) in Indian children. Indian Pediatr, 57:1010–14.

Ding, Y., Yan, H., Guo, W. (2020). Clinical characteristics of children with COVID-19: a meta-analysis. Front Pediatr, 8:431.

Dosanjh, A. (2020). Eosinophil-derived neurotoxin and respiratory tract infection and inflammation: implications for COVID 19 management. J Interferon Cytokine Res, 40:443–5.

Feldstein, L. R., Rose, E.B., Horwitz, S.M., Collins, J.P., Newhams, M.M., Son, M. et al. (2020). Overcoming COVID-19 Investigators and the CDC COVID-19 Response Team. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med, 383:334–46.

Gralinski, L. E., Bankhead, A. R., Jeng, S. et al. (2013). Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. Mbio, 4(4):e00271–e313

Guan, W. J., ZY, N. I., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X. et al. (2020). China medical treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 382:1708–20.

Guan, W., Ni, Z., Hu, Y. et al. (2020). Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv.

Gunther, A., Mosavi, P., Heinemann, S., Ruppert, C., Muth, H., Markart, P., Grimminger, F., Walmrath, D. (2000). Temmesfeld-Wollbruck B., Seeger W. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med, 161(2-1):454–462

Hanson, K. E., Caliendo, A. M., Arias, C. A., Englund, J. A., Lee, M. J., Loeb, M. et al. (2020). Infectious diseases society of America guidelines on the diagnosis of COVID-19. Clin Infect Dis.

He, X., Lau, E. H. Y., Wu, P. et al. (2020).Temporal dynamics in viral shedding and transmissibility of COVID-19. Nature Medicine.

Hou, H., Zhang, B., Huang, H., Luo, Y., Wu, S., Tang, G. et al. (2020). Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19. Clin Exp Immunol, 201:76–84.

Huang, C., Wang, Y., Li X. et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395(10223):497–506.

Huang, I., Pranata, R. (2020). Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care, 8:36.

Hui, D. S., Wong, P. C., Wang, C. (2003). SARS: clinical features and diagnosis. Respirology, 8(Suppl):S20–S24

Lagunas-Rangel, F. A. (2020). Neutrophil-to-lymphocyte ratio and lymphocyte-to- C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. J Med Virol, 92:1733–4.

Lang, Z., Zhang, L., Zhang, S., Meng, X., Li, J., Song, C., Sun, L., Zhou, Y. (2003). Pathological study on severe acute respiratory syndrome. Chin Med J Peking, 07:17–21.

Li, Q., Guan, X., Wu, P.et al.(2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The New England journal of medicine, 382(13):1199–1207.

Lippi, G., Plebani, M. (2020). Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta, 505:190–1.

Liu, R., Ma, Q., Han, H., Su, H., Liu, F., Wu, K. et al. (2020). The value of urine biochemical parameters in the prediction of the severity of coronavirus disease 2019. Clin Chem Lab Med, 58:1121–4.

Liu, R., Wang, Y., Li, J., Han, H., Xia, Z., Liu, F. et al. (2020). Decreased T cell populations contribute to the increased severity of COVID-19. Clin Chim Acta, 508:110–4.

Liu, T., Zhang, J., Yang, Y., Ma, H., Li, Z., Zhang, J. et al. (2020). The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med, 12:e12421.

Ma, A., Cheng, J., Yang, J., Dong, M., Liao, X., Kang, Y. (2020). Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients. Crit Care, 24:288.

Mao, L., Wang, M., Chen, S. et al. (2020). Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. medRxiv.

Mustafa, M. A., AL-Samarraie, M. Q., Ahmed, M. T. (2020). Molecular techniques of viral diagnosis. Science Archives, 1(3):89-92.

Patel, A., Jernigan, D. B. (2020). nCo VCDCRT. Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak – United States, December 31, 2019-February 4, 2020. MMWR Morb Mortal Wkly Rep, 69(5):140–146.

Petherick, A. (2020). Developing antibody tests for SARS-CoV-2. The Lancet, 395(10230):1101–1102.

Pettila, V., Hynninen, M., Takkunen, O., Kuusela, P., Valtonen, M. (2002) Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med 28(9):1220–1225

Ranjan, A., Chauhan, A., Gurnani, M., & Jindal, T. (2020). Potential phytochemicals as efficient protease inhibitors of 2019-nCoV.

Salluh, J., Rabello, L., Rosolem, M.M., Soares, M., Bozza, F.A., Verdeal, J., Mello, G.W., Castro, F.N.H., Lapa, E.S.J., Bozza, P.T. (2011). The impact of coagulation parameters on the outcomes of patients with severe community-acquired pneumonia requiring intensive care unit admission. J Crit Care, 26(5):496–501

Shorr, A. F., Thomas, S. J., Alkins, S. A., Fitzpatrick, T. M., Ling, G. S. (2002). D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest, 121(4):1262–1268

Singh-Grewal, D., Lucas, R., McCarthy, K., Cheng, A. C., Wood, N., Ostring, G. et al. (2020). Update on the COVID-19-associated inflammatory syndrome in children and adolescents; paediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2. J Paediatr Child Health, 56:1173–77.

Snijders, D., Schoorl, M., Schoorl, M., Bartels, P.C., van der Werf, T.S., Boersma, W.G. (2012). D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia. A secondary analysis of a randomised clinical trial. Eur J Intern Med, 23(5):436–441.

Tan, L., Wang, Q., Zhang, D., Ding, J., Huang, Q., Tang, Y.Q. et al. (2020). Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther, 5:33.

Tan, W., Zhao, X., Ma, X., Wang, W., Niu, P., Xu, W., Gao, G.F., Wu, G. (2020). A novel coronavirus genome identified in a cluster of pneumonia cases—Wuhan, China 2019–2020. China CDC Wkly, 2(4):61–62.

Tang, N., Li, D., Wang, X., Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost, 18(4):844–847.

Tang, Y. W., Schmitz, J. E., Persing, D. H., Stratton, C. W. (2020). The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges. J Clin Microbiol.

Terpos, E., Ntanasis-Stathopoulos, I., Elalamy, I., Kastritis, E., Sergentanis, T.N., Politou, M.et al. (2020). Hematological findings and complications of COVID-19. Amer J Hematol, 95:834–47.

To, K.K., Tsang, O.T., Leung, W.S. et al. (2020). Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis.

Tsang, K. W., Ho, P. L., Ooi, G. C. et al. (2003). A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med,  348(20):1977–1985.

Urra, J. M., Cabrera, C. M., Porras, L., Ródenas, I. (2020). Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients. Clin Immunol, 217:108486.

van Belle, A., Buller, H. R., Huisman, M. V. et al. (2006). Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA, 295(2):172–179.

Wang, D., Hu, B., Hu, C. et al. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 323(11):1061–1069.

Wang, G., Wu, C., Zhang, Q., Wu, F., Yu, B., Lv, J. et al. (2020). C-Reactive protein level may predict the risk of COVID-19 aggravation. Open Forum Infect Dis, 7:ofaa153.

Wölfel, R., Corman, V. M., Guggemos, W. et al. (2020). Virological assessment of hospitalized patients with COVID-2019. Nature.

World Health Organization. Naming the Coronavirus Disease (COVID-19 and the Virus That Causes it. (2020). Available online at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/namingthe-coronavirus-disease-(covid-2019)-and-the-virus-that-causesit

Wu, Z. and McGoogan, J. M. (2020). Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA.

Xu, Z., Shi, L., Wang, Y. et al. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 8(4):420–422.

Yan, X., Li, F., Wang, X., Yan, J., Zhu, F., Tang, S. et al. (2019). Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: a retrospective cross-sectional study. J Med Virol, 92:2573–81.

Yang, J., Zhao, X., Liu, X., Sun, W., Zhou, L., Wang, Y. et al. (2020). Clinical characteristics and eosinophils in young SARS-CoV-2-positive chinese travelers returning to shanghai. Front Public Health, 8:368.

Zheng, Y., Zhang, Y., Chi, H., Chen, S., Peng, M., Luo, L. et al. (2020). The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study. Clin Chem Lab Med, 58:1106–15.

Zhou, P., Yang, X. L., Wang, X. G. et al.  (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798):270–273.

License              Article Metadata

This work is licensed under a Creative Commons Attribution 4.0 International License.